> top > docs > PubMed:10068112 > annotations

PubMed:10068112 JSONTXT

Annnotations TAB JSON ListView MergeView

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 282-307 HP_0004448 denotes fulminant hepatic failure
T2 292-307 HP_0001399 denotes hepatic failure
T3 300-316 HP_0001399 denotes failure to liver
T4 827-852 HP_0004448 denotes fulminant hepatic failure
T5 837-852 HP_0001399 denotes hepatic failure

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 190-1191 OBJECTIVE denotes There is an urgent need for an effective bioartificial liver system to bridge patients with fulminant hepatic failure to liver transplantation or to regeneration of their own liver. Recently, we proposed a bioreactor with a novel design for use as a bioartificial liver (BAL). The reactor comprises a spirally wound nonwoven polyester fabric in which hepatocytes are cultured (40 x 10(6) cells/ml) as small aggregates and homogeneously distributed oxygenation tubing for decentralized oxygen supply and CO2 removal. The aims of this study were to evaluate the treatment efficacy of our original porcine hepatocyte-based BAL in rats with fulminant hepatic failure due to liver ischemia (LIS) and to monitor the viability of the porcine hepatocytes in the bioreactor during treatment. The latter aim is novel and was accomplished by applying a new species-specific enzyme immunoassay (EIA) for the determination of porcine alpha-glutathione S-transferase (alpha-GST), a marker for hepatocellular damage.
T2 1201-1550 METHODS denotes Three experimental groups were studied: the first control group (LIS Control, n = 13) received a glucose infusion only; a second control group (LIS No-Cell-BAL, n = 8) received BAL treatment without cells; and the treated group (LIS Cell-BAL, n = 8) was connected to our BAL which had been seeded with 4.4 x 10(8) viable primary porcine hepatocytes.
T3 1572-2233 CONCLUSIONS denotes In contrast to previous comparable studies, BAL treatment significantly improved survival time in recipients with LIS. In addition, the onset of hepatic encephalopathy was significantly delayed and the mean arterial blood pressure significantly improved. Significantly lower levels of ammonia and lactate in the LIS Cell-BAL group indicated that the porcine hepatocytes in the bioreactor were metabolically activity. Low pig alpha-GST levels suggested that our bioreactor was capable of maintaining hepatocyte viability during treatment. These results provide a rationale for a comparable study in LIS-pigs as a next step towards potential clinical application.